30 / 33
Borghaei et al. WCLC 2017, Reck et al. NEJM 2016, Leighl et al JCO 2017, Sandler et al. NEJM 2006, Schiller et al. NEJM 2002
PD1 2nd line
Chemotherapy
Anti-VEGF
How much improve in NSCLC?
Proportion Surviving
PD1 1st line
51.5% at 2ys
IO-CT1st line
70% at 18 months